000518 Jiangsu Sihuan Bioengineering
- 2.40
- +0.11+4.80%
Jiangsu Sihuan Bioengineering News
Sihuan Biotech (000518.SZ): Appoints Zhao Jie as Chief Financial Officer
Sihuan Biotech (000518.SZ) issued an announcement, nominated by the company's chairman and reviewed by the nomination committee of the company's board of directors...
Express News | Sihuan Biotech: Subsidiary included in the list of untrustworthy executees
Sihuan Biology (000518.SZ): Chenwei Ecological Park was included in the list of untrustworthy executees
Gelonghui, March 25 | Sihuan Biology (000518.SZ) announced that the company recently learned through the China Executive Information Disclosure Network that its wholly-owned subsidiary Jiangsu Chenwei Ecological Park Technology Co., Ltd. (“Chenwei Ecological Park”) was included in the list of untrustworthy executioners.
Tetracyclics (000518.SZ): No specific drug type for lupus erythematosus
On December 15, Gelonghui Biotech (000518.SZ) stated on the investor interactive platform that the company has no specific drug for lupus erythematosus disease.
Pharmaceutical stocks fell, Siyuan Biotech fell to a standstill in the intraday period
Gelonghui November 29 | Sihuan Biotech fell to a standstill in the intraday period, and Guangdong Wannianqing fell nearly 7%. Special Pharmaceutical, Tailong Pharmaceutical, Panlong Pharmaceutical, and Kunyao Group had the highest declines.
4 Connect to Sihuan Biotech: There have been no major changes in the company's business situation or internal and external business environment recently
Gelonghui November 27 | Sihuan Biotech announced on November 27 that for two consecutive trading days (November 24, 2023, November 27, 2023), the cumulative increase in the closing price deviation value of the company's stock was more than 20%, which is an abnormal fluctuation in stock trading. There have been no major changes in the company's business conditions or internal or external business environment recently.
Pharmaceutical stocks continue to be active on Sihuan Biotech's fourth consecutive board
On November 27, Gelonghui | Sihuan Biotech Group 4, Lianhuan Pharmaceutical Company 3, Lugang Pharmaceutical, Guangshengtang, Duori Pharmaceutical, and Harbin Pharmaceutical Co., Ltd. all opened higher.
Pharmaceutical stocks continue to strengthen Sihuan Biotech's 3rd consecutive board
On November 24, Gelonghui | Sihuan Biotech's third board, Lianhuan Pharmaceutical rose and stopped, Guangdong Wannianqing rose more than 10%, and Longshen Rongfa, Teyi Pharmaceutical, and Lu Kang Pharmaceutical rose more than 5%. According to the news, data released by the Beijing Center for Disease Control and Prevention shows that the number of influenza cases is rising rapidly. The influenza virus nucleic acid positive rate in outpatient clinics exceeds 40%, and various other pathogens are common.
A-share review: The Beijing Stock Exchange Index fell 2.78% and stopped rising four times in a row! Auto parts for automobiles, virus prevention concepts, etc. registered the highest gains
Gelonghui November 23 | Major A-share indices rose slightly in the afternoon. By the close, the Shanghai Index had risen 0.6% to 3061 points, the Shenzhen Stock Exchange Index had risen 0.78%, and the GEM Index had risen 0.58%; the Beijing Stock Exchange 50 Index fell 2.78%, stopping four consecutive gains. Nearly 4,200 shares in the two markets rose, trading for 824.2 billion yuan throughout the day, and the net purchase of capital going north was 5.058 billion yuan. On the market, auto parts stocks were strong throughout the day, with multiple stocks such as Dolly Technology and Anton Power leading the way; pediatric visits in many places surged, and the concept of virus prevention and control continued to be active in the afternoon; Sihuan Biology and Lianhuan Pharmaceutical both rose and stopped; the lidar sector rose, Wanjike
A-share afternoon review: the three major indices have had mixed ups and downs, and the concept of virus prevention has risen and stopped, and Changan Automobile has risen and stopped!
Gelonghui November 23 | The three major A-share indices fluctuated slightly. By the midday closing, the Shanghai Index had risen 0.17% to 3048 points, the Shenzhen Stock Exchange Index had risen 0.28%, and the GEM Index had fallen 0.07%. More than 3,700 shares in the two markets rose, with half-day transactions of 522.1 billion yuan, and a net purchase of 1,333 billion yuan by capital going north. On the market, the number of pediatric visits to many regions surged, and the concept of virus prevention and control was active in early trading, and Sihuan Biotech was connected to 2 boards; OpenAI opened ChatGPT Voice for free, smart voice concept stocks rose, and Weishi Electronics was connected to the 3rd board; “2024 total hydrofluorocarbon quota setting and distribution plan
The concept of virus prevention and control was active in the early trading of Cyclic Biology 2
On November 23, Gelonghui | Sihuan Biotech's second board, Guilin Sanjin and Tailong Pharmaceutical rose and stopped, while Weikang Pharmaceutical, Teyi Pharmaceutical, and Huluwa had the highest gains. According to the news, Wang Quanyi, deputy director of the Beijing Center for Disease Control and Prevention and chief epidemiology expert, said that the top three causes of treatment were influenza, adenovirus, and respiratory syncytial virus in pediatric hospitals such as the Beijing Children's Hospital and the First Nursery School.
Sihuan Biotech (000518.SZ) released results for the first three quarters, with a net loss of 43,317,500 yuan
Sihuan Biotech (000518.SZ) released its report for the first three quarters. During the reporting period, the company achieved revenue of 180 million yuan...
Sihuan Biotech: A case was filed where the actual controller is suspected of manipulating the securities market in violation of laws and regulations
Glonghui, Oct. 9 | Sihuan Biotech announced that the actual controller, Lu Keping, is suspected of violating the law by manipulating the securities market, and the China Securities Regulatory Commission has decided to file a case against him.
Interpretation of Sihuan Biotech's 2023 Interim Report: Operating income increased slightly, net profit was under pressure, and net cash flow declined sharply
According to Sihuan Biotech's 2023 interim report, the company's revenue for the reporting period was 121,411,354.73 yuan, an increase of 2.55% compared to 118,397,374.09 yuan in the same period last year. This indicates that the company has grown in terms of operations, but it has increased slightly. However, net profit attributable to shareholders of listed companies during the reporting period was -37,775,397.48 yuan, down 14.72% from -32,927,209.66 yuan in the same period last year. At the same time, net profit attributable to shareholders of listed companies during the reporting period after deducting non-recurring profit and loss was -3
Sihuan Biotech (000518.SZ): Net loss of 377.75 million yuan in the first half of the year
Gelonghui, August 22丨Sihuan Biotech (000518.SZ) released its semi-annual report. Revenue was 121 million yuan, up 2.55% year on year, net loss of 37.775 million yuan, net loss of 37.775 million yuan, net loss of 379.349 million yuan, net loss of 379.349 million yuan per share, and a basic loss of 0.0367 yuan per share.
Sihuan Biotech (000518.SZ) made an estimated loss and is expected to have a net loss of 30 million yuan to 60 million yuan in the first half of the year
According to the Zhitong Finance App, Sihuan Biotech (000518.SZ) released its 2023 semi-annual results forecast. Net losses attributable to shareholders of listed companies in the first half of the year are estimated to be 30 million yuan to 60 million yuan. The loss is estimated to be 30.3 million yuan to 60.6 million yuan after deducting non-recurring profit and loss. The main reason for the company's performance loss during the reporting period was: during the reporting period, the holding subsidiary Beijing Sihuan Biopharmaceutical Co., Ltd. saw a slight increase in profit from the same period last year, but it was still a loss; the engineering dispute between the wholly-owned subsidiary Jiangsu Chenwei Ecological Park Technology Co., Ltd. and Rugao Lvsifang Landscaping Engineering Co., Ltd. received a civil judgment.
Sihuan Biotech (000518.SZ) issued first-quarter results, with a net loss of 1,9591,000 yuan
According to the Zhitong Finance App, Sihuan Biotech (000518.SZ) released a report for the first quarter of 2023, achieving revenue of 57.013,500 yuan, an increase of 13.22% over the previous year. The net loss attributable to shareholders of listed companies was 1,9591 million yuan. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was $1,418,500.
Sihuan Biotech (000518.SZ) issued 2022 results, with a net loss of 487.928 million yuan
According to the Zhitong Finance App, Sihuan Biotech (000518.SZ) released its 2022 annual report, achieving revenue of 270 million yuan, a year-on-year decrease of 23.03%. The net loss attributable to shareholders of listed companies was 487.928 million yuan. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 49,646,700.
Sihuan Biotech (000518.SZ) forecasted losses, with a net loss of about 43 million yuan to 86 million yuan in 2022
According to the Zhitong Finance App, Sihuan Biotech (000518.SZ) released its 2022 annual performance forecast. Net profit attributable to shareholders of listed companies was about -86 million yuan to -43 million yuan, compared to -34.7899 million yuan for the same period last year. Net profit after deducting non-recurring profit and loss is about -88 million yuan to -44 million yuan.
000518.SZ posted a net loss of 35.3556 million yuan for the first three quarters of the year.
Zhitong Financial APP News, fourth Ring Biology (000518.SZ) released the third quarter report of 2022, the first three quarters operating income of 197 million yuan, down 16.76% from the same period last year. The net loss attributable to the shareholders of the listed company is 35.3556 million yuan. The net loss of 35.404 million yuan after deducting non-recurring profits and losses belonging to the shareholders of the listed company. Basic earnings per share-0.0343 yuan.
Analysis
Price Target
No Data
